DDInter1702 DDInter1938
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Sorafenib {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Vincristine
Sorafenib {u} (Compound) binds {v} (Gene) RALBP1
RALBP1 {u} (Gene) is bound by {v} (Compound) Vincristine
Sorafenib {u} (Compound) downregulates {v} (Gene) TUBB4B
TUBB4B {u} (Gene) is bound by {v} (Compound) Vincristine
Sorafenib {u} (Compound) upregulates {v} (Gene) GRB10
GRB10 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Sorafenib {u} (Compound) downregulates {v} (Gene) CCNB1
CCNB1 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Sorafenib {u} (Compound) binds {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Sorafenib {u} (Compound) downregulates {v} (Gene) HACD3
HACD3 {u} (Gene) is downregulated by {v} (Compound) Vincristine
Sorafenib {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Vincristine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Sorafenib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Vincristine (Compound)
Sorafenib (Compound) binds RALBP1 (Gene) and RALBP1 (Gene) is bound by Vincristine (Compound)
Sorafenib (Compound) downregulates TUBB4B (Gene) and TUBB4B (Gene) is bound by Vincristine (Compound)
Sorafenib (Compound) upregulates GRB10 (Gene) and GRB10 (Gene) is upregulated by Vincristine (Compound)
Sorafenib (Compound) downregulates CCNB1 (Gene) and CCNB1 (Gene) is upregulated by Vincristine (Compound)
Sorafenib (Compound) binds STK10 (Gene) and STK10 (Gene) is upregulated by Vincristine (Compound)
Sorafenib (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) is downregulated by Vincristine (Compound)
Sorafenib (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Vincristine (Compound)